Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

CPRXNYSE / NASDAQHealthcareMid cap

$31.49$0.00 (0.0%)

Last close · Data as of Jul 21, 2026

Market cap
$3.8B
P/E
17.9x
EV / EBITDA
10.6x
Revenue
$589.0M
Net margin
36.4%
ROCE
26.9%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Catalyst Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 21 Jul 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $31 to $31 · Last close Jul 21, 2026

Best weekday to invest, historically

The same weekly amount in CPRX, bought on each weekday since 2021.

News & filings

What Catalyst Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 43.8% against a peer median of 12.7%.

Concerns

No concern stands out for this company on the data on file.

  • Prices are as of 21 Jul 2026; price-based points are paused until newer prices arrive.

Prices to the 21 Jul 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.

Read moreShow less

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Sector
Healthcare
Shares outstanding
122.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.8B
P/E
17.9x
P/B
4.0x
EV / EBITDA
10.6x
EV / Sales
5.3x
P/S
6.5x
52-week high
$31.50
52-week low
$19.13

Profitability

Operating margin
43.8%
Net margin
36.4%
EBITDA margin
50.2%
ROE
22.5%
ROCE
26.9%
ROA
19.4%
Asset turnover
0.53

Growth

Revenue
$589.0M
Revenue growth, 1Y
19.8%
Revenue CAGR, 3Y
40.1%
Net profit growth, 1Y
30.8%
Free cash flow
$208.6M

Solvency

Current ratio
6.08
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
0.97
Cash / Market cap
18.5%

Where the revenue went

Of every $100 of FY2025 revenue, $36 was left as net income.

Catalyst Pharmaceuticals, Inc. income statement flow, FY2025
Catalyst Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$87.3M
RevenueGross profit$501.7M
Gross profitResearch and development$12.7M
Gross profitSelling, general and administrative$193.8M
Gross profitOther operating expenses$37.5M
Gross profitOperating income$257.8M
Operating incomePretax income$257.8M
Interest and other incomePretax income$25.7M
Pretax incomeTax and other$69.2M
Pretax incomeNet income$214.3M

Revenue and net profit

Revenue grew 19.8% in FY2025; net profit is the dashed line.

Catalyst Pharmaceuticals, Inc. revenue and net profit by fiscal year
Catalyst Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$214.2M$83.1M
FY2023$398.2M$71.4M
FY2024$491.7M$163.9M
FY2025$589.0M$214.3M

Cash flows

FY2025: $208.7M from operations, $208.6M free after investment (dashed).

Catalyst Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Catalyst Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$116.0M$116.0M
FY2023$143.6M$61.9M
FY2024$239.8M$239.3M
FY2025$208.7M$208.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$589.0M+19.8%1Y
EBITDA
$295.7M+26.9%1Y
Net profit
$214.3M+30.8%1Y
Cash from operations
$208.7M-13.0%1Y
Free cash flow
$208.6M-12.8%1Y
Revenue CAGR, 3Y
40.1%
Net profit CAGR, 3Y
37.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$589.0M$295.7M$214.3M$208.6M22.5%+19.8%+30.8%

Monthly returns

Month-by-month returns of CPRX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.1B
Liabilities$149.7M
Equity$954.3M
Paid-in capital$480.0M
Retained earnings$474.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CPRX highlighted.

P/E against peers

CPRX trades at 17.9x earnings against a peer median of 31.9x (a 44% discount).

Not shown (no positive earnings and no EV / Sales): RadNet, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Catalyst Pharmaceuticals, Inc.CPRXthis companyP/E ↓ discount$3.8B17.9x4.0x22.5%10.6x
Amneal Pharmaceuticals, Inc.AMRX$4.3B59.9x-60.9x-101.8%11.1x
RadNet, Inc.RDNT$4.2B-222.6x3.8x-1.7%16.7x
Veracyte, Inc.VCYT$4.0B60.1x3.0x5.1%40.9x
Waystar Holding Corp.WAY$3.9B34.6x1.0x2.9%13.6x
Merit Medical Systems, Inc.MMSI$3.8B29.3x2.4x8.1%12.5x
ACADIA Pharmaceuticals Inc.ACAD$3.7B9.5x3.0x31.9%30.8x
Organon & Co.OGN$3.5B18.8x4.7x24.9%9.0x
ICU Medical, Inc.ICUI$3.4B4607.1x1.6x0.0%14.7x
Peer median—31.9x2.7x4.0%14.1x

Year-to-date ROI

CPRX since 1 January, against earlier years.

Historical volatility

CPRX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Catalyst Pharmaceuticals, Inc. operating margin by fiscal year
Catalyst Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY202247.5%
FY202321.8%
FY202439.7%
FY202543.8%
LineFY2025
Cost of revenueCost Of Revenue$87.3M
Gross profitGross Profit$501.7M
Operating expensesOperating Expense$244.0M
Research and developmentResearch And Development$12.7M
Depreciation and amortisationDepreciation And Amortization In Income Statement$37.5M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$37.5M
Amortization$37.5M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$37.5M
Total expensesTotal Expenses$331.2M
Pretax incomePretax Income$283.5M

Learn while you research

Academy chapters picked for Catalyst Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →